Speakers

 

 

Elsa Abranches, Chief Scientific Officer, ViSync Technologies

Amina Al-Mossawi, Qualified Person, MeiraGTx

Amina Al-Mossawi | Qualified Person | MeiraGTx » speaking at Advanced Therapies UK

Nicola Ambler, Founder, The CGT Circle

Nicola Ambler | Founder | The CGT Circle » speaking at Advanced Therapies UK

Peter Andersen, Chief Research & Development Officer, Treefrog Therapeutics

Peter Andersen | Chief Research & Development Officer | Treefrog Therapeutics » speaking at Advanced Therapies UK

Catia Andreassi, Director, AviadoBio

Catia Andreassi | Director | AviadoBio » speaking at Advanced Therapies UK

Marta Arrizabalaga Cascallana, PhD Researcher, UCL

Marta Arrizabalaga Cascallana | PhD Researcher | UCL » speaking at Advanced Therapies UK

Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust

Owen Bain | Director | Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust » speaking at Advanced Therapies UK

Ricardo Baptista, Chief Technology Officer, Smartcella

Ricardo Baptista | Chief Technology Officer | Smartcella » speaking at Advanced Therapies UK

Ivana Barbaric, Professor of Stem Cell Biology, The University of Sheffield

Ivana Barbaric | Professor of Stem Cell Biology | The University of Sheffield » speaking at Advanced Therapies UK

Samantha Barber, Chief Executive Officer, Gene People

Samantha Barber | Chief Executive Officer | Gene People » speaking at Advanced Therapies UK

Kate Barclay, Skills Strategy Consultant, UK Bioindustry Association

Kate Barclay | Skills Strategy Consultant | UK Bioindustry Association » speaking at Advanced Therapies UK

Mark Battaglini, Chief Strategy Officer, Alliance for Regenerative Medicine

Mark Battaglini | Chief Strategy Officer | Alliance for Regenerative Medicine » speaking at Advanced Therapies UK

Elena Beltrami, Investment Manager, Biotech Venture Advisors

Elena Beltrami | Investment Manager | Biotech Venture Advisors » speaking at Advanced Therapies UK

Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, University College London

Sara Benedetti | Group Leader, Assistant Professor in Gene Therapy | University College London » speaking at Advanced Therapies UK

Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon

Stefano Benvenuti | Head of Public Affairs and Market Access | Fondazione Telethon » speaking at Advanced Therapies UK

Katja Berg, Global Value and Access Strategy, BBU, AstraZeneca

Katja Berg | Global Value and Access Strategy, BBU | AstraZeneca » speaking at Advanced Therapies UK

Dr. Niklas Beschorner, Head of Rnd, PROVIREX Genome Editing Therapies GmbH

Dr. Niklas Beschorner | Head of Rnd | PROVIREX Genome Editing Therapies GmbH » speaking at Advanced Therapies UK

Gaurav Bhavsar, Technical Director, Gene Therapy Vector Facility (GTVF), King's College London

Gaurav Bhavsar | Technical Director, Gene Therapy Vector Facility (GTVF) | King's College London » speaking at Advanced Therapies UK

Katie Binley, Chief Scientific Officer, Ikarovec Limited

Katie Binley | Chief Scientific Officer | Ikarovec Limited » speaking at Advanced Therapies UK

Anne Black, QA Specialist Pharmacist, NHS Specialist Pharmacy Service

Anne Black | QA Specialist Pharmacist | NHS Specialist Pharmacy Service » speaking at Advanced Therapies UK

Alex Blyth, Founder & CEO, Lift Biosciences Ltd

Alex Blyth | Founder & CEO | Lift Biosciences Ltd » speaking at Advanced Therapies UK

Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center

Jaap Jan Boelens | Chief, Transplantation and Cellular Therapies | Memorial Sloan-Kettering Cancer Center » speaking at Advanced Therapies UK

Angela Borghouts - de Ruijter, Associate Director Market Access, Gilead Sciences

Angela Borghouts - de Ruijter | Associate Director Market Access | Gilead Sciences » speaking at Advanced Therapies UK

Jonathan Bracey, Founder, MVA Society

John Bridgeman, Chief Scientific Officer, Immunokey

John Bridgeman | Chief Scientific Officer | Immunokey » speaking at Advanced Therapies UK

Simon Briggs, Director, Advanced Analytics, Orchard Therapeutics

Simon Briggs | Director, Advanced Analytics | Orchard Therapeutics » speaking at Advanced Therapies UK

Leigh Brody, Investment Manager, AlbionVC

Leigh Brody | Investment Manager | AlbionVC » speaking at Advanced Therapies UK

Ross Bunyan, External Manufacturing Lead, Resolution Therapeutics

Ross Bunyan | External Manufacturing Lead | Resolution Therapeutics » speaking at Advanced Therapies UK

Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences

Henriette Burghoorn | Associate Director, Market Access | Gilead Sciences » speaking at Advanced Therapies UK

Cherith Campbell-Bell, Director of Clinical Development, Rinri Therapeutics

Amanda Jayne Carr, Associate Professor, Institute of Ophthalomolgy U.C.L.

Amanda Jayne Carr | Associate Professor | Institute of Ophthalomolgy U.C.L. » speaking at Advanced Therapies UK

Manuel Carrondo, Vice-President, iBET: Instituto de Biologia Experimental e Tecnológica

Manuel Carrondo | Vice-President | iBET: Instituto de Biologia Experimental e Tecnológica » speaking at Advanced Therapies UK

Paul Carter, Senior Director, MSAT, Quell Therapeutics

Paul Carter | Senior Director, MSAT | Quell Therapeutics » speaking at Advanced Therapies UK

Anna-Lina Cavallo, Director Discovery Cell and Gene Therapy integrated Bioanalysis, AstraZeneca

Anna-Lina Cavallo | Director Discovery Cell and Gene Therapy integrated Bioanalysis | AstraZeneca » speaking at Advanced Therapies UK

Dr Prasun Chakraborty, CEO and Founder, Genevation LTD

Dr Prasun Chakraborty | CEO and Founder | Genevation LTD » speaking at Advanced Therapies UK

Carolyn Chan, Senior Specialist Clinical Trials (ATIMPs) and QA Pharmacist, Great Ormond Street Hospital

Carolyn Chan | Senior Specialist Clinical Trials (ATIMPs) and QA Pharmacist | Great Ormond Street Hospital » speaking at Advanced Therapies UK

Alison Clare, Senior Research Associate, University of Bristol

Alison Clare | Senior Research Associate | University of Bristol » speaking at Advanced Therapies UK

Angela Columbano, Head Business Development and Partnership, Genethon

Angela Columbano | Head Business Development and Partnership | Genethon » speaking at Advanced Therapies UK

Jean-Philippe Combal, Co-Founder & Chief Executive Officer, Vivet Therapeutics

Jean-Philippe Combal | Co-Founder & Chief Executive Officer | Vivet Therapeutics » speaking at Advanced Therapies UK

Pedro Correa de Sampaio, CEO, Neobe Therapeutics

Pedro Correa de Sampaio | CEO | Neobe Therapeutics » speaking at Advanced Therapies UK

Randolph Corteling, Chief Scientific Officer, ReNeuron

Randolph Corteling | Chief Scientific Officer | ReNeuron » speaking at Advanced Therapies UK

John Counsell, Associate Professor, UCL

John Counsell | Associate Professor | UCL » speaking at Advanced Therapies UK

Matthieu Coutet, Partner, Sofinnova Partners

Vicki Coutinho, Managing Director & Consultant, Geni Consulting

Vicki Coutinho | Managing Director & Consultant | Geni Consulting » speaking at Advanced Therapies UK

Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, University College London

Claudiu Cozmescu | Postdoctoral Researcher, Gissen Lab | University College London » speaking at Advanced Therapies UK

Salmaan Dalvi, Chief Executive Officer, Global Regenerative Medicine Society

Salmaan Dalvi | Chief Executive Officer | Global Regenerative Medicine Society » speaking at Advanced Therapies UK

Annalucia Darbey, Postdoctoral Research Fellow, University College London

Annalucia Darbey | Postdoctoral Research Fellow | University College London » speaking at Advanced Therapies UK

Eric Michael David, Chief Executive Officer of Gene Therapy, BridgeBio

Eric Michael David | Chief Executive Officer of Gene Therapy | BridgeBio » speaking at Advanced Therapies UK

Lindsay Davies, CSO, NextCell Pharma

Maike de la Roche, Senior Group Leader, The Cancer Research UK Cambridge Institute (CRUK-CI)

Marc de la Roche, Asst. Professor, Dept. of Biochemistry, University of Cambridge

Marc de la Roche | Asst. Professor, Dept. of Biochemistry | University of Cambridge » speaking at Advanced Therapies UK

Brett Doble, Director HEOR, Australia/Canada/Europe (ACE), HEOR Center of Excellence, Kite, a Gilead Company

Brett Doble | Director HEOR, Australia/Canada/Europe (ACE), HEOR Center of Excellence | Kite, a Gilead Company » speaking at Advanced Therapies UK

Fabien Dorange, Director Analytical Sciences, SparingVision

Fabien Dorange | Director Analytical Sciences | SparingVision » speaking at Advanced Therapies UK

Marcus Droege, Chief Commercial Officer, MUVON Therapeutics

Marcus Droege | Chief Commercial Officer | MUVON Therapeutics » speaking at Advanced Therapies UK

Beatriz Duran, Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust

Beatriz Duran | Head of Clinical Trials Pharmacy Service and ATMPs | Manchester University NHS Foundation Trust » speaking at Advanced Therapies UK

Omer Dushek, Professor of Molecular Immunology, University of Oxford

Omer Dushek | Professor of Molecular Immunology | University of Oxford » speaking at Advanced Therapies UK

Joseph Egan, Research Associate, Teesside University

Joseph Egan | Research Associate | Teesside University » speaking at Advanced Therapies UK

Jiri Eitler, Group Leader - NK Cell Therapy, Dresden University of Technology

Jiri Eitler | Group Leader - NK Cell Therapy | Dresden University of Technology » speaking at Advanced Therapies UK

Tim Farries, Independent Consultant Cell & Gene Therapies, Independent

Tim Farries | Independent Consultant Cell & Gene Therapies | Independent » speaking at Advanced Therapies UK

Jay Feinberg, President, WMDA

Jay Feinberg | President | WMDA » speaking at Advanced Therapies UK

Paulo Fernandes, Senior Director, Technical Operations, Spur Therapeutics

Paulo Fernandes | Senior Director, Technical Operations | Spur Therapeutics » speaking at Advanced Therapies UK

Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association

Katherine Forsey | Chief Research Officer | Charcot Marie Tooth Association » speaking at Advanced Therapies UK

Mr Miguel Forte, CEO, Kiji Tx

Mr Miguel Forte | CEO | Kiji Tx » speaking at Advanced Therapies UK

Daniel Fowler, Research Fellow, UCL

Daniel Fowler | Research Fellow | UCL » speaking at Advanced Therapies UK

George Frodsham, Founder & CEO, MediSieve Limited

George Frodsham | Founder & CEO | MediSieve Limited » speaking at Advanced Therapies UK

Toby Gamlen, Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of Sheffield

Toby Gamlen | Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre | University of Sheffield » speaking at Advanced Therapies UK

Holly Garlick, Head of GMP, Gene Therapy Innovation & Manufacturing Centre, University of Sheffield

Holly Garlick | Head of GMP, Gene Therapy Innovation & Manufacturing Centre | University of Sheffield » speaking at Advanced Therapies UK

Bobby Gaspar, Chief Executive Officer, Orchard Therapeutics

Bobby Gaspar | Chief Executive Officer | Orchard Therapeutics » speaking at Advanced Therapies UK

Paul Gissen, Clinical Professor of Paediatric Metabolic Medicine, UCL Great Ormond Street Institute of Child Health

Janet Glassford, Expert Quality Assessor, Biologicals Unit, Medicines & Healthcare products Regulatory Agency

Janet Glassford | Expert Quality Assessor, Biologicals Unit | Medicines & Healthcare products Regulatory Agency » speaking at Advanced Therapies UK

Roberto Gramignoli, Associate Professor, Karolinska Institutet

Roberto Gramignoli | Associate Professor | Karolinska Institutet » speaking at Advanced Therapies UK

Uta Griesenbach, Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy;, Imperial College London

Uta Griesenbach | Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy; | Imperial College London » speaking at Advanced Therapies UK

Brad Groves, Director, NICE Advice, NICE

Brad Groves | Director, NICE Advice | NICE » speaking at Advanced Therapies UK

Professor Nagy Habib, Professor of Surgery, Imperial College London

Professor Nagy Habib | Professor of Surgery | Imperial College London » speaking at Advanced Therapies UK

Rachel Haines, VP, Clinical Development and Operations, Rinri Therapeutics

Rachel Haines | VP, Clinical Development and Operations | Rinri Therapeutics » speaking at Advanced Therapies UK

Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA

Brian Harrison, Director, Hitech Health

Brian Harrison | Director | Hitech Health » speaking at Advanced Therapies UK

Luke Henry, Chief Business Officer, Quell Therapeutics

Luke Henry | Chief Business Officer | Quell Therapeutics » speaking at Advanced Therapies UK

Victor Hernandez, CSO, Axovia therapeutics

Victor Hernandez | CSO | Axovia therapeutics » speaking at Advanced Therapies UK

Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan

Diana Hernandez | Director of Immune and Advanced Therapies | Anthony Nolan » speaking at Advanced Therapies UK

Ulf Holmgren, Global Pricing and Market Access Director, AstraZeneca

Ulf Holmgren | Global Pricing and Market Access Director | AstraZeneca » speaking at Advanced Therapies UK

Lilian Hook, Director of Cell, Aphaeresis and Gene Therapies, NHS Blood and Transplant

Lilian Hook | Director of Cell, Aphaeresis and Gene Therapies | NHS Blood and Transplant » speaking at Advanced Therapies UK

Melita Irving, Group Leader at the Ludwig Institute for Cancer Research, University of Lausanne

Melita Irving | Group Leader at the Ludwig Institute for Cancer Research | University of Lausanne » speaking at Advanced Therapies UK

Mark Jarvis, Director of Advanced Therapies, Newcastle upon Tyne Hospitals NHS Foundation Trust

Mark Jarvis | Director of Advanced Therapies | Newcastle upon Tyne Hospitals NHS Foundation Trust » speaking at Advanced Therapies UK

Pia Johansson, Director, Cell and Gene Therapy Core, Lund University

Pia Johansson | Director, Cell and Gene Therapy Core | Lund University » speaking at Advanced Therapies UK

Natalie Johnston, Principal, 4BIO CAPITAL

Natalie Johnston | Principal | 4BIO CAPITAL » speaking at Advanced Therapies UK

Margareth Jorvid, Board Member, Elicera Therapeutics

Margareth Jorvid | Board Member | Elicera Therapeutics » speaking at Advanced Therapies UK

Manel Juan, Head of Immunology Service, Hospital Clínic de Barcelona

Manel Juan | Head of Immunology Service | Hospital Clínic de Barcelona » speaking at Advanced Therapies UK

Tom Kamperman, Founder & CTO, IamFluidics BV

Tom Kamperman | Founder & CTO | IamFluidics BV » speaking at Advanced Therapies UK

Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London

Sophia Karagiannis | Professor of Translational Cancer Immunology and Immunotherapy | King's College London » speaking at Advanced Therapies UK

Claire Kerridge, Head of Gene Therapy, MHRA

Claire Kerridge | Head of Gene Therapy | MHRA » speaking at Advanced Therapies UK

Abdullah Khan, Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow, University of Oxford

Abdullah Khan | Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow | University of Oxford » speaking at Advanced Therapies UK

Rahul Khetan, Venture Associate, UCB Ventures

Rahul Khetan | Venture Associate | UCB Ventures » speaking at Advanced Therapies UK

Azadeh Kia, VP Gene Therapy Research, Beacon Therapeutics

Azadeh Kia | VP Gene Therapy Research | Beacon Therapeutics » speaking at Advanced Therapies UK

Sven Kili, Partner, Saisei Ventures

Sven Kili | Partner | Saisei Ventures » speaking at Advanced Therapies UK

Kerstin Kinkelin, Innovation Lead, Bristol BioDesign Institute, University of Bristol

Kerstin Kinkelin | Innovation Lead, Bristol BioDesign Institute | University of Bristol » speaking at Advanced Therapies UK

Janine Kirby, Professor, University of Sheffield

Janine Kirby | Professor | University of Sheffield » speaking at Advanced Therapies UK

Evangelia Kokalaki, Director, Immunobiology, Autolus Therapeutics

Evangelia Kokalaki | Director, Immunobiology | Autolus Therapeutics » speaking at Advanced Therapies UK

Anna Koptina, Head Of Regulatory Affairs, Mendus

Anna Koptina | Head Of Regulatory Affairs | Mendus » speaking at Advanced Therapies UK

Kat Kozyrytska, Founder, Cell Therapy Manufacturability Program

Kat Kozyrytska | Founder | Cell Therapy Manufacturability Program » speaking at Advanced Therapies UK

Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd

Mathias Kroll | Chief Business Officer | Cynata Therapeutics Ltd » speaking at Advanced Therapies UK

Sandeep Kumar, Head of Advanced Therapy Production, Guy's and St Thomas' NHS Foundation Trust

Sandeep Kumar | Head of Advanced Therapy Production | Guy's and St Thomas' NHS Foundation Trust » speaking at Advanced Therapies UK

David Kuntin, Chief Executive Officer, Mesenbio

David Kuntin | Chief Executive Officer | Mesenbio » speaking at Advanced Therapies UK

Michael Kyriakides, Investment partner, Syncona Ltd

Michael Kyriakides | Investment partner | Syncona Ltd » speaking at Advanced Therapies UK

Nico Lachmann, Professor, Hannover Medical School

Nico Lachmann | Professor | Hannover Medical School » speaking at Advanced Therapies UK

Holger Laux, Director of Genetic Medicine, CSL Behring

Holger Laux | Director of Genetic Medicine | CSL Behring » speaking at Advanced Therapies UK

Inês Leal Reis, Co-founder, Regenera

Inês Leal Reis | Co-founder | Regenera » speaking at Advanced Therapies UK

Roger Legtenberg, Co-Founder, Partners4Patients Foundation

Roger Legtenberg | Co-Founder | Partners4Patients Foundation » speaking at Advanced Therapies UK

Giulia Leonetti, Policy Officer, European Commission

Giulia Leonetti | Policy Officer | European Commission » speaking at Advanced Therapies UK

Michelle Levene, Managing Director, 161 Consulting Ltd

Michelle Levene | Managing Director | 161 Consulting Ltd » speaking at Advanced Therapies UK

James Levine, President, Fondation Ipsen

James Levine | President | Fondation Ipsen » speaking at Advanced Therapies UK

Weiwei Li, Highly Specialist Clinical Trials Pharmacist (HaemOnc), Guy's and St Thomas NHS Foundation Trust

Weiwei Li | Highly Specialist Clinical Trials Pharmacist (HaemOnc) | Guy's and St Thomas NHS Foundation Trust » speaking at Advanced Therapies UK

Luke Lindsay-Hill, Head of Cell Therapy, Biotherapeutics Advanced Therapies, MHRA

Luke Lindsay-Hill | Head of Cell Therapy, Biotherapeutics Advanced Therapies | MHRA » speaking at Advanced Therapies UK

Rosie Lindup, Senior Policy and Public Affairs Manager, BioIndustry Association (BIA)

Rosie Lindup | Senior Policy and Public Affairs Manager | BioIndustry Association (BIA) » speaking at Advanced Therapies UK

Patricia Longo, CMC Sr. Staff Scientist, Regeneron

Patricia Longo | CMC Sr. Staff Scientist | Regeneron » speaking at Advanced Therapies UK

Mark Lowdell, CSO, INmuneBio

Mark Lowdell | CSO | INmuneBio » speaking at Advanced Therapies UK

Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute

Alejandro Madrigal, OBE FMedSci | Professor of Haematology | UCL Cancer Institute » speaking at Advanced Therapies UK

John Maher, CSO, Leucid Bio

Heather Main, Co-Founder, HOYA consulting

Heather Main | Co-Founder | HOYA consulting » speaking at Advanced Therapies UK

Harris Makatsoris, Professor of Manufacturing, King's College London

Harris Makatsoris | Professor of Manufacturing | King's College London » speaking at Advanced Therapies UK

Alberto Malerba, Lecturer in Gene Therapy, Royal Holloway University of London

Alberto Malerba | Lecturer in Gene Therapy | Royal Holloway University of London » speaking at Advanced Therapies UK

Salah Mansour, Associate Professor, iNKT cell therapy, University of Southampton

Salah Mansour | Associate Professor, iNKT cell therapy | University of Southampton » speaking at Advanced Therapies UK

Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca

Marcello Maresca | Senior Director - Genome Engineering | AstraZeneca » speaking at Advanced Therapies UK

Marc Martinez-Llordella, Founder and VP Biology, Quell Therapeutics

Marc Martinez-Llordella | Founder and VP Biology | Quell Therapeutics » speaking at Advanced Therapies UK

Nazia Matto, sATMP scientist, GMP Facility, Tower wing, Guys Hospital

Nazia Matto | sATMP scientist | GMP Facility, Tower wing, Guys Hospital » speaking at Advanced Therapies UK

Dave Mentlak, Senior Scientist, Mesenbio

Dave Mentlak | Senior Scientist | Mesenbio » speaking at Advanced Therapies UK

Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills, Lifearc

Anji Miller | Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills | Lifearc » speaking at Advanced Therapies UK

Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine

Paolo Morgese | Vice President, Public Affairs, Europe | Alliance for Regenerative Medicine » speaking at Advanced Therapies UK

David Morrow, Senior Scientific Programme Manager-ATMP/Vaccines, EATRIS

David Morrow | Senior Scientific Programme Manager-ATMP/Vaccines | EATRIS » speaking at Advanced Therapies UK

Sophie Mountcastle, Network Manager - Innovation Hubs for Gene Therapies, Innovation Hubs for Gene Therapies

Sophie Mountcastle | Network Manager - Innovation Hubs for Gene Therapies | Innovation Hubs for Gene Therapies » speaking at Advanced Therapies UK

Noor Mujahid, Head of Vector Process Development, NHS Centre for Cell Gene and Tissue Therapeutics

Noor Mujahid | Head of Vector Process Development | NHS Centre for Cell Gene and Tissue Therapeutics » speaking at Advanced Therapies UK

Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center

Claudio Mussolino | Group Leader - Genome and Epigenome Engineering | Freiburg University Medical Center » speaking at Advanced Therapies UK

Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Darren Nesbeth, Associate Professor, University College London

Darren Nesbeth | Associate Professor | University College London » speaking at Advanced Therapies UK

Katy Newton, Chief Scientific Officer, MFX

Katy Newton | Chief Scientific Officer | MFX » speaking at Advanced Therapies UK

Joanne Ng, Professor of Genetic Therapy, UCL Institute of Neurology

Joanne Ng | Professor of Genetic Therapy | UCL Institute of Neurology » speaking at Advanced Therapies UK

Roberto Nitsch, Director, AstraZeneca

Roberto Nitsch | Director | AstraZeneca » speaking at Advanced Therapies UK

Hugh O'Brien, CTO, Lir Therapeutics

Hugh O'Brien | CTO | Lir Therapeutics » speaking at Advanced Therapies UK

Daniel O'Connor, Director, Regulatory Policy & Early Access, ABPI

Raphael Ognar, President & Chief Executive Officer, Co-Founder, NKILT Therapeutics Inc.

Raphael Ognar | President & Chief Executive Officer, Co-Founder | NKILT Therapeutics Inc. » speaking at Advanced Therapies UK

Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Matias Olsen | Senior Manager, Public Affairs & Policy | EUCOPE - European Confederation of Pharmaceutical Entrepreneurs » speaking at Advanced Therapies UK

Dominic O'Regan, Business Development Consultant & Investor, New Mosaic

Dominic O'Regan | Business Development Consultant & Investor | New Mosaic » speaking at Advanced Therapies UK

Andrew Palfreeman, Associate Director, R&D Lab Core and Operations, Quell Therapeutics

Andrew Palfreeman | Associate Director, R&D Lab Core and Operations | Quell Therapeutics » speaking at Advanced Therapies UK

Kerstin Papenfuss, Director Pharma, Deep Science Ventures

Kerstin Papenfuss | Director Pharma | Deep Science Ventures » speaking at Advanced Therapies UK

Efstratia Papoutselou, Patient and Public Involvement Lead, Rinri Therapeutics

Efstratia Papoutselou | Patient and Public Involvement Lead | Rinri Therapeutics » speaking at Advanced Therapies UK

Adam Parnaby, Lead, Global Policy & Access, BMS

Adam Parnaby | Lead, Global Policy & Access | BMS » speaking at Advanced Therapies UK

Kathryn Parsley, VP, Regulatory Affairs, Complement Therapeutics

Kathryn Parsley | VP, Regulatory Affairs | Complement Therapeutics » speaking at Advanced Therapies UK

Hamza Patel, Lead Advanced Therapies (Cell & Gene) Specialist Clinical Trial Pharmacist, Great Ormond Street Hospital for Children

Hamza Patel | Lead Advanced Therapies (Cell & Gene) Specialist Clinical Trial Pharmacist | Great Ormond Street Hospital for Children » speaking at Advanced Therapies UK

Tanya Patel, Senior Manager CTSM, BioNTech

Tanya Patel | Senior Manager CTSM | BioNTech » speaking at Advanced Therapies UK

Dilip Patel, SVP, Access & Market Development, Autolus

Dilip Patel | SVP, Access & Market Development | Autolus » speaking at Advanced Therapies UK

Tom Payne, Chief Operating Officer, Laverock Therapeutics

Tom Payne | Chief Operating Officer | Laverock Therapeutics » speaking at Advanced Therapies UK

David Peritt, Chief Scientific Officer, Lupagen

David Peritt | Chief Scientific Officer | Lupagen » speaking at Advanced Therapies UK

Ana Plata, Head of Global Access, Respiratory & Immunology, AstraZeneca

Ana Plata | Head of Global Access, Respiratory & Immunology | AstraZeneca » speaking at Advanced Therapies UK

Riccardo Privolizzi, Senior Research Fellow and Associate Lecturer, University College London

Juliette Pulman, Research Fellow, INSERM

Juliette Pulman | Research Fellow | INSERM » speaking at Advanced Therapies UK

Monica Raimo, Director of Product and Process Development, Glycostem Therapeutics

Monica Raimo | Director of Product and Process Development | Glycostem Therapeutics » speaking at Advanced Therapies UK

Lior Raviv, CTO, Pluri

Lior Raviv | CTO | Pluri » speaking at Advanced Therapies UK

Nicola Redfern, Director, NJ Redfern Ltd.

Nicola Redfern | Director | NJ Redfern Ltd. » speaking at Advanced Therapies UK

Vik Reebye, Head of Academic Partnership, MiNA Therapeutics Ltd

Vik Reebye | Head of Academic Partnership | MiNA Therapeutics Ltd » speaking at Advanced Therapies UK

Andrew Roddam, Chief Business Development Officer, EveryONE Medicines

Andrew Roddam | Chief Business Development Officer | EveryONE Medicines » speaking at Advanced Therapies UK

Ali Roghanian, Associate Prof in Cancer Immunotherapy, University of Southampton

Ali Roghanian | Associate Prof in Cancer Immunotherapy | University of Southampton » speaking at Advanced Therapies UK

Antonio Roldao, Head of Cell-based Vaccines Development Lab, IBET

Antonio Roldao | Head of Cell-based Vaccines Development Lab | IBET » speaking at Advanced Therapies UK

Alex Ross, Head of NHS Cord Bank, NHS Blood and Transplant

Alex Ross | Head of NHS Cord Bank | NHS Blood and Transplant » speaking at Advanced Therapies UK

Sean Russell, Head of Regulatory Affairs, Telethon Foundation

Sean Russell | Head of Regulatory Affairs | Telethon Foundation » speaking at Advanced Therapies UK

Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.

Tara Sadeghi | Chief Operating Officer | Cellenkos Inc. » speaking at Advanced Therapies UK

Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis

Arthur Sagoskin | Chief Executive Officer & Co-Founder | Mygogenesis » speaking at Advanced Therapies UK

Jorge Salazar, Head of Process Development, INmuneBio

Jorge Salazar | Head of Process Development | INmuneBio » speaking at Advanced Therapies UK

Moin Saleem, Founder and Chief Scientific Advisor, Purespring Therapeutics

Moin Saleem | Founder and Chief Scientific Advisor | Purespring Therapeutics » speaking at Advanced Therapies UK

Avencia Sánchez-Mejías García, CEO & Co-founder, Integra Therapeutics

Avencia Sánchez-Mejías García | CEO & Co-founder | Integra Therapeutics » speaking at Advanced Therapies UK

Dominic Schmidt, General Partner, Advent Life Sciences

Dominic Schmidt | General Partner | Advent Life Sciences » speaking at Advanced Therapies UK

Gerty Schreibelt, Assistant Professor / Immunologist, Radboud University Medical Centre

Gerty Schreibelt | Assistant Professor / Immunologist | Radboud University Medical Centre » speaking at Advanced Therapies UK

Sujith Sebastian, Viral Vector Hub Manager, Clinical Biotechnology Centre, NHSBT

Sujith Sebastian | Viral Vector Hub Manager | Clinical Biotechnology Centre, NHSBT » speaking at Advanced Therapies UK

Marta Serafini, Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca

Marta Serafini | Associate Professor, School of Medicine and Surgery | University of Milano-Bicocca » speaking at Advanced Therapies UK

Lior Shaltiel, Chief Executive Officer, NurExone Biologic

Chrysanthi Sitmalidou, Scientist II, Orchard Therapeutics

Chrysanthi Sitmalidou | Scientist II | Orchard Therapeutics » speaking at Advanced Therapies UK

Owen Smith, Partner, 4BIO CAPITAL

Owen Smith | Partner | 4BIO CAPITAL » speaking at Advanced Therapies UK

Sarah Snykers, Head of Operations, Legend Biotech

Sarah Snykers | Head of Operations | Legend Biotech » speaking at Advanced Therapies UK

Oliver Spadiut, Head of the Research Area Biochemical Engineering, TU Wien

Oliver Spadiut | Head of the Research Area Biochemical Engineering | TU Wien » speaking at Advanced Therapies UK

Molly Stevens, John Black Professor of Bionanoscience, University of Oxford

Nicola Stoner, Consultant Pharmacist - Cancer & ATMPs, Oxford University Hospitals NHS Foundation Trust

Nicola Stoner | Consultant Pharmacist - Cancer & ATMPs | Oxford University Hospitals NHS Foundation Trust » speaking at Advanced Therapies UK

Siddharth Subramaniam, Senior Policy and Public Affairs Executive, BIA

Siddharth Subramaniam | Senior Policy and Public Affairs Executive | BIA » speaking at Advanced Therapies UK

Stephen Sullivan, Director, Lindville Bio

Stephen Sullivan | Director | Lindville Bio » speaking at Advanced Therapies UK

Marina Tarunina, Research Director, Plasticell

Marina Tarunina | Research Director | Plasticell » speaking at Advanced Therapies UK

Urvi Thacker, Associate Director, MSAT, Quell Therapeutics

Urvi Thacker | Associate Director, MSAT | Quell Therapeutics » speaking at Advanced Therapies UK

Panteli Theocharous, Chief Therapeutics Officer and Head of Medical and Scientific Affairs, Stratus Therapeutics

Panteli Theocharous | Chief Therapeutics Officer and Head of Medical and Scientific Affairs | Stratus Therapeutics » speaking at Advanced Therapies UK

Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics

Stefanos Theoharis | Chief Executive Officer | OneChain Immunotherapeutics » speaking at Advanced Therapies UK

Samantha Thomas, Head of Research, ReNeuron

Samantha Thomas | Head of Research | ReNeuron » speaking at Advanced Therapies UK

Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol

Ash Toye | Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics | University of Bristol » speaking at Advanced Therapies UK

Olivier Tramis, Senior Research Scientist, University of Strasbourg

Olivier Tramis | Senior Research Scientist | University of Strasbourg » speaking at Advanced Therapies UK

Pamela Tranter, Head, Translational Research Group (TRO), University College London

Pamela Tranter | Head, Translational Research Group (TRO) | University College London » speaking at Advanced Therapies UK

Marco Traub, Chief Executive Officer, Tesct—Society

Marco Traub | Chief Executive Officer | Tesct—Society » speaking at Advanced Therapies UK

Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics

Kristian Tryggvason | Chief Executive Officer | Alder Therapeutics » speaking at Advanced Therapies UK

Giandomenico Turchiano, Associate Director, Cell & Gene therapy Safety, AstraZeneca

Giandomenico Turchiano | Associate Director, Cell & Gene therapy Safety | AstraZeneca » speaking at Advanced Therapies UK

David Uguen, SVP, Head of Regulatory Affairs, Orchard Therapeutics

David Uguen | SVP, Head of Regulatory Affairs | Orchard Therapeutics » speaking at Advanced Therapies UK

Hiro Usuda, Scouting & Transaction Lead, Business Development, Astellas

Hiro Usuda | Scouting & Transaction Lead, Business Development | Astellas » speaking at Advanced Therapies UK

Renaud Vaillant, CEO & co-Founder, Alaya.bio

Renaud Vaillant | CEO & co-Founder | Alaya.bio » speaking at Advanced Therapies UK

Sonia Valero, Head Of Clinical Operations - Patient Advocacy Leader, Vivet Therapeutics

Sonia Valero | Head Of Clinical Operations - Patient Advocacy Leader | Vivet Therapeutics » speaking at Advanced Therapies UK

Joshi Venugopal, General Manager and Head of Europe, Novartis Gene Therapies

Joshi Venugopal | General Manager and Head of Europe | Novartis Gene Therapies » speaking at Advanced Therapies UK

Raul Villamarin Rodriguez, Vice President, Woxsen University

Raul Villamarin Rodriguez | Vice President | Woxsen University » speaking at Advanced Therapies UK

Ketki Vispute, Associate Director, MSAT, Autolus

Ketki Vispute | Associate Director, MSAT | Autolus » speaking at Advanced Therapies UK

Valentin von Werz, PhD Researcher, TU Wien

Valentin von Werz | PhD Researcher | TU Wien » speaking at Advanced Therapies UK

Arsalan Wafi, Academic Clinical Lecturer, King´s College London

Arsalan Wafi | Academic Clinical Lecturer | King´s College London » speaking at Advanced Therapies UK

Alain Wagner, Director of Research, CNRS

Alain Wagner | Director of Research | CNRS » speaking at Advanced Therapies UK

Simon Walker, Head of MSAT, Gene Therapy Vector Facility, Kings College London

Simon Walker | Head of MSAT | Gene Therapy Vector Facility, Kings College London » speaking at Advanced Therapies UK

Piers Walser, Lead Development Scientist, Clinical Biotechnology Centre, NHSBT

Piers Walser | Lead Development Scientist | Clinical Biotechnology Centre, NHSBT » speaking at Advanced Therapies UK

Emily Warner, Principal Scientist, Ikarovec Limited

Emily Warner | Principal Scientist | Ikarovec Limited » speaking at Advanced Therapies UK

Ben Weil, Chief Operating Officer & Chief Manufacturing Officer, INmuneBio

Ben Weil | Chief Operating Officer & Chief Manufacturing Officer | INmuneBio » speaking at Advanced Therapies UK

Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading

Darius Widera | Professor of Stem Cell Biology and Regenerative Medicine | University of Reading » speaking at Advanced Therapies UK

Chris Williams, Chief Business Officer, Autolus

Chris Williams | Chief Business Officer | Autolus » speaking at Advanced Therapies UK

Shao-An Xue, Professor, Zhengzhou University of Technology

Shao-An Xue | Professor | Zhengzhou University of Technology » speaking at Advanced Therapies UK

Ilya Yasny, Partner, LanceBio Ventures

Ilya Yasny | Partner | LanceBio Ventures » speaking at Advanced Therapies UK

Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National Institutes of Health

Nan Zhang | Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering | National Institutes of Health » speaking at Advanced Therapies UK

Federica Zinghirino, Postdoctoral Research Fellow, UCL

Federica Zinghirino | Postdoctoral Research Fellow | UCL » speaking at Advanced Therapies UK

Cem Zorlular, CEO, Er-Kim Pharmaceuticals

Cem Zorlular | CEO | Er-Kim Pharmaceuticals » speaking at Advanced Therapies UK


Get Involved with Advanced Therapies Congress

 

To sponsor or exhibit

Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

To speak

Chris Shanks
Chris.Shanks@terrapinn.com
+44 207 092 1150